Ducray, F.; Ramirez, C.; Robert, M.; Fontanilles, M.; Bronnimann, C.; Chinot, O.; Estrade, F.; Durando, X.; Cartalat, S.; Bastid, J.;
et al. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics 2023, 15, 2664.
https://doi.org/10.3390/pharmaceutics15122664
AMA Style
Ducray F, Ramirez C, Robert M, Fontanilles M, Bronnimann C, Chinot O, Estrade F, Durando X, Cartalat S, Bastid J,
et al. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics. 2023; 15(12):2664.
https://doi.org/10.3390/pharmaceutics15122664
Chicago/Turabian Style
Ducray, François, Carole Ramirez, Marie Robert, Maxime Fontanilles, Charlotte Bronnimann, Olivier Chinot, Florian Estrade, Xavier Durando, Stéphanie Cartalat, Jeremy Bastid,
and et al. 2023. "A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules" Pharmaceutics 15, no. 12: 2664.
https://doi.org/10.3390/pharmaceutics15122664
APA Style
Ducray, F., Ramirez, C., Robert, M., Fontanilles, M., Bronnimann, C., Chinot, O., Estrade, F., Durando, X., Cartalat, S., Bastid, J., Bienayme, H., & Lemarchand, C.
(2023). A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules. Pharmaceutics, 15(12), 2664.
https://doi.org/10.3390/pharmaceutics15122664
